Emergent BioSolutions Secures $60M+ in New Smallpox Defense Contracts
Emergent BioSolutions wins $54M U.S. government contract for VIGIV plus $6.6M international orders for ACAM2000 smallpox vaccine.
Already have an account? Sign in.